1-3 of 3
Yun Su, MD MPH, MS
Close
Sort by
Journal Articles

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Matthias Stelljes, MD, Yun Su, MD MPH, MS, Kyle Fahrbach, PhD, Erik Vandendries, MD PhD, Veronique Page, M.Sc, Uchenna Onyekwere, MD MPh, Yunyang Wang, M.Sc, M.Pharm, Joseph C. Cappelleri, PhD MPH, MS, Irina Proskorovsky, M.Sc
Journal: Blood
Blood (2017) 130 (Supplement 1): 2558.
https://doi.org/10.1182/blood.V130.Suppl_1.2558.2558
Published: 2017
Journal Articles

Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices

Thomas W. LeBlanc, MD MA, Azah Borham, PharmD, Yun Su, MD MPH, MS, Karin Chun Hayes, Russel Fielding, Michael Benigno, MA, Joseph C. Cappelleri, PhD MPH, MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1328.
https://doi.org/10.1182/blood.V130.Suppl_1.1328.1328
Published: 2017
Journal Articles

The Effect of Vascular Occlusive Events on Discontinuation and Cost of Care in Patients Treated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Stuart L. Goldberg, MD, Yun Su, MD MPH, MS, Candace Gunnarsson, EdD, MA, William D Irish, PhD, Michael Ryan, MS, Mabel Woloj, MD, Roxanne Ferdinand, MBBS MRCP MFPM, Mark Shapiro, MD
Journal: Blood
Blood (2015) 126 (23): 2797.
https://doi.org/10.1182/blood.V126.23.2797.2797
Published: 2015